|
[1] YOUNOSSI ZM,KOENIG AB,ABDELATIF D,et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes[J]. Hepatology,2016,64(1):73-84.
|
|
[2] Chinese Society of Endocrinology,Chinese Medical Association. Consensus for diagnosis and treatment of nonalcoholic fatty liver diseases and metabolic disorders(2nd Edition)[J].J Clin Hepatol,2018,34(10):2103-2108.(in Chinese)中华医学会内分泌学分会．非酒精性脂肪性肝病与代谢相关紊乱诊疗共识(第二版)[J]．临床肝胆病杂志，2018,34(10):2103-2108.
|
|
[3] BARB D,PORTILLO-SANCHEZ P,CUSI K. Pharmacological management of nonalcoholic fatty liver disease[J]. Metabolism,2016,65(8):1183-1195.
|
|
[4] YOUNOSSI ZM,GOLABI P,DE AVILA L,et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes:A systematic review and meta-analysis[J]. J Hepatol,2019,71(4):793-801.
|
|
[5] EGUCHI Y,KITAJIMA Y,HYOGO H,et al. Pilot study of liraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients(LEAN-J)[J]. Hepatol Res,2015,45(3):269-278.
|
|
[6] PETIT JM,CERCUEIL JP,LOFFROY R,et al. Effect of liraglutide therapy on liver fat content in patients with inadequately controlled type 2 diabetes:The lira-NAFLD study[J]. J Clin Endocrinol Metab,2017,102(2):407-415.
|
|
[7] RIZVI AA,PATTI AM,GIGLIO RV,et al. Liraglutide improves carotid intima-media thickness in patients with type 2 diabetes and non-alcoholic fatty liver disease:An 8-month prospective pilot study[J]. Expert Opin Biol Ther,2015,15(10):1391-1397.
|
|
[8] ARMSTRONG MJ,HOULIHAN DD,ROWE IA,et al. Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes:Individual patient data meta-analysis of the LEAD program[J]. Aliment Pharmacol Ther,2013,37(2):234-242.
|
|
[9] FENG WH,BI Y,LI P,et al. Effects of liraglutide,metformin and gliclazide on body composition in patients with both type 2diabetes and non-alcoholic fatty liver disease:A randomized trial[J]. J Diabetes Investig,2019,10(2):399-407.
|
|
[10] MANTOVANI A,BYRNE CD,SCORLETTI E,et al. Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes:An updated systematic review of randomized controlled trials[J]. Diabetes Metab,2020.[Online ahead of print]
|
|
[11] YAN J,YAO B,KUANG H,et al. Liraglutide,sitagliptin,and insulin glargine added to metformin:The effect on body weight and intrahepatic lipid in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease[J]. Hepatology,2019,69(6):2414-2426.
|
|
[12] TIAN F,ZHENG Z,ZHANG D,et al. Efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease[J]. Biosci Rep,2018,38(6):BSR20181304.
|
|
[13] SMITS MM,TONNEIJCK L,MUSKIET MH,et al. Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes:A randomised placebo-controlled trial[J]. Diabetologia,2016,59(12):2588-2593.
|
|
[14] SMITH BW,ADAMS LA. Nonalcoholic fatty liver disease and diabetes mellitus:Pathogenesis and treatment[J]. Nat Rev Endocrinol,2011,7(8):456-465.
|
|
[15] QIU H,YANG JK,CHEN C. Influence of insulin on growth hormone secretion,level and growth hormone signalling[J]. Acta Physiol Sin,2017,69(5):541-556.(in Chinese)邱涵，杨金奎，陈晨．胰岛素对生长激素的分泌和细胞内信号传导的影响[J]．生理学报，2017,69(5):541-556.
|
|
[16] SHI ZP,YANG Y,LEI Y,et al. Liraglutide ameliorates hepatic expression of c-Jun N-terminal protein kinase in type 2 diabetic rats with nonalcoholic fatty liver diseas[J]. Chin J Diabetes,2016,8(9):548-553.(in Chinese)石志平，杨昱，雷营，等．利拉鲁肽降低2型糖尿病伴非酒精性脂肪性肝病大鼠肝脏磷酸化c-Jun氨基末端激酶的蛋白表达[J]．中华糖尿病杂志，2016,8(9):548-553.
|
|
[17] SZEGEZDI E,LOGUE SE,GORMAN AM,et al. Mediators of endoplasmic reticulum stress-induced apoptosis[J]. EMBO Rep,2006,7(9):880-885.
|
|
[18] KIM I,XU W,REED JC. Cell death and endoplasmic reticulum stress:Disease relevance and therapeutic opportunities[J].Nat Rev Drug Discov,2008,7(12):1013-1030.
|
|
[19] ZHAO L,ACKERMAN SL. Endoplasmic reticulum stress in health and disease[J]. Curr Opin Cell Biol,2006,18(4):444-452.
|
|
[20] XU K,WANG X,SHI Q,et al. Human prion protein mutants with deleted and inserted octarepeats undergo different pathways to trigger cell apoptosis[J]. J Mol Neurosci,2011,43(3):225-234.
|
|
[21] LAMPROPOULOU E,LYMPEROPOULOU A,CHARONIS A.Reduced expression of ERp46 under diabetic conditions inβ-cells and the effect of liraglutide[J]. Metabolism,2016,65(1):7-15.
|
|
[22] AO N,YANG J,WANG X,et al. Glucagon-like peptide-1preserves non-alcoholic fatty liver disease through inhibition of the endoplasmic reticulum stress-associated pathway[J].Hepatol Res,2016,46(4):343-353.
|
|
[23] KAZANKOV K,JRGENSEN S,THOMSEN KL,et al. The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis[J]. Nat Rev Gastroenterol Hepatol,2019,16(3):145-159.
|
|
[24] LUO W,XU Q,WANG Q,et al. Effect of modulation of PPAR-γactivity on Kupffer cells M1/M2 polarization in the development of non-alcoholic fatty liver disease[J]. Sci Rep,2017,7:44612.
|
|
[25] SOHN W,JUN DW,LEE KN,et al. Lactobacillus paracasei Induces M2-dominant Kupffer cell polarization in a mouse model of nonalcoholic steatohepatitis[J]. Dig Dis Sci,2015,60(11):3340-3350.
|
|
[26] LECLERCQ IA,FARRELL GC,SEMPOUX C,et al. Curcumin inhibits NF-kappaB activation and reduces the severity of experimental steatohepatitis in mice[J]. J Hepatol,2004,41(6):926-934.
|
|
[27] YU J,IP E,DELA PEA A,et al. COX-2 induction in mice with experimental nutritional steatohepatitis:Role as pro-inflammatory mediator[J]. Hepatology,2006,43(4):826-836.
|
|
[28] LUO Y,YANG P,LI Z,et al. Liraglutide improves non-alcoholic fatty liver disease in diabetic mice by modulating inflammatory signaling pathways[J]. Drug Des Devel Ther,2019,13:4065-4074.
|
|
[29] ZHOU JY,POUDEL A,WELCHKO R,et al. Liraglutide improves insulin sensitivity in high fat diet induced diabetic mice through multiple pathways[J]. Eur J Pharmacol,2019,861:172594.
|
|
[30] GUO S. Insulin signaling,resistance,and the metabolic syndrome:Insights from mouse models into disease mechanisms[J]. J Endocrinol,2014,220(2):T1-T23.
|
|
[31] BOUCHER J,KLEINRIDDERS A,KAHN CR. Insulin receptor signaling in normal and insulin-resistant states[J]. Cold Spring Harb Perspect Biol,2014,6(1):a009191.
|
|
[32] RONCERO I,ALVAREZ E,ACOSTA C,et al. Insulin-receptor substrate-2(irs-2)is required for maintaining glucokinase and glucokinase regulatory protein expression in mouse liver[J]. PLo S One,2013,8(4):e58797.
|
|
[33] YONEYAMA Y,LANZERSTORFER P,NIWA H,et al. IRS-1acts as an endocytic regulator of IGF-I receptor to facilitate sustained IGF signaling[J]. Elife,2018,7:e32893.
|
|
[34] KUBOTA N,TOBE K,TERAUCHI Y,et al. Disruption of insulin receptor substrate 2 causes type 2 diabetes because of liver insulin resistance and lack of compensatory beta-cell hyperplasia[J]. Diabetes,2000,49(11):1880-1889.
|
|
[35] YANG P,LIANG Y,LUO Y,et al. Liraglutide ameliorates nonalcoholic fatty liver disease in diabetic mice via the IRS2/PI3K/Akt signaling pathway[J]. Diabetes Metab Syndr Obes,2019,12:1013-1021.
|
|
[36] POLYZOS SA,KOUNTOURAS J,ZAVOS C,et al. The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease[J]. Diabetes Obes Metab,2010,12(5):365-383.
|
|
[37] HSIEH CJ,WANG PW,HU TH. Association of adiponectin gene polymorphism with nonalcoholic fatty liver disease in Taiwanese patients with type 2 diabetes[J]. PLo S One,2015,10(6):e0127521.
|
|
[38] FINKEL T,DENG CX,MOSTOSLAVSKY R. Recent progress in the biology and physiology of sirtuins[J]. Nature,2009,460(7255):587-591.
|
|
[39] XU F,LI Z,ZHENG X,et al. SIRT1 mediates the effect of GLP-1 receptor agonist exenatide on ameliorating hepatic steatosis[J]. Diabetes,2014,63(11):3637-3646.
|
|
[40] DENG XQ,CHEN LL,LI NX. The expression of SIRT1 in nonalcoholic fatty liver disease induced by high-fat diet in rats[J]. Liver Int,2007,27(5):708-715.
|
|
[41] PFLUGER PT,HERRANZ D,VELASCO-MIGUEL S,et al.Sirt1 protects against high-fat diet-induced metabolic damage[J]. Proc Natl Acad Sci U S A,2008,105(28):9793-9798.
|
|
[42] RODGERS JT,PUIGSERVER P. Fasting-dependent glucose and lipid metabolic response through hepatic sirtuin 1[J].Proc Natl Acad Sci U S A,2007,104(31):12861-12866.
|
DownLoad: